ADHD Study Identifies Neural Biotypes for Treatment
Raffaele Di Giacomo discussed a new study identifying ADHD biotypes via neural profiles that could enable personalized treatments, raising questions about impacts on medication and therapy approaches. Separately, Zia Learning cited research reframing ADHD as a reward-processing issue rather than attention deficit, urging engaging personalized learning over forced focus methods.
- The study on neural biotypes for ADHD utilized functional network connectivity data from 1069 patients in the Adolescent Brain and Cognitive Development (ABCD) study to identify two distinct biotypes. - These biotypes demonstrated different responses to medication; biotype 1 showed a significantly better recovery with methylphenidate, while biotype 2 responded better to atomoxetine. - The biotypes also corresponded to different clinical profiles, with biotype 1 having generally milder symptoms, whereas biotype 2 exhibited more severe hyperactivity/impulsivity and lower cognitive levels. - The theory of ADHD as a reward-processing issue suggests that altered dopamine function in the brain's reward system can lead to a reduced sensitivity to rewards. - This reward-processing difference can manifest as a preference for smaller, immediate rewards over larger, delayed ones—a concept known as delay discounting. - Research has shown that individuals with ADHD have lower levels of dopamine receptors and transporters in key brain regions associated with motivation and reward. - A study from King's College London identified a specific gene, VPS4A, that may regulate dopamine levels and is associated with reward anticipation, potentially providing a genetic link to the reward-processing challenges in ADHD. - The ultimate goal of identifying ADHD biotypes is to move towards a more personalized medicine approach, where treatment is guided by an individual's specific neurobiology rather than trial-and-error.
